Motavizumab
Motavizumab
Motavizumab (pronunciation: mo-ta-vi-zu-mab) is a monoclonal antibody that was designed for the prevention of severe lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in pediatric patients at high risk of RSV disease.
Etymology
The name "Motavizumab" is derived from the Latin roots "mota" meaning "movement", and "vizumab", a common suffix for monoclonal antibodies.
Usage
Motavizumab works by binding to the F protein on the surface of the RSV, preventing the virus from entering the cells and thus inhibiting viral replication. It was developed by MedImmune, a subsidiary of AstraZeneca.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Respiratory Syncytial Virus: A common respiratory virus that usually causes mild, cold-like symptoms.
- F protein: A type of protein on the surface of the RSV that allows the virus to enter cells.
- MedImmune: A biotechnology company that develops vaccines and antibody-based drugs.
- AstraZeneca: A British-Swedish multinational pharmaceutical and biopharmaceutical company.
See Also
- Palivizumab: A humanized monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infection.
- Monoclonal Antibodies: A type of immunotherapy that uses monoclonal antibodies to treat cancer.
External links
- Medical encyclopedia article on Motavizumab
- Wikipedia's article - Motavizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski